Dragon Appoints Ernst & Young LLP as Company's Auditor and Intends to Apply For American Stock Exchange Listing

Dragon Appoints Ernst & Young LLP as Company's Auditor and
Intends to Apply For American Stock Exchange Listing 


VANCOUVER, July 12  /PRNewswire-FirstCall/ -- Dragon Pharmaceutical Inc. (OTC
BB: DRUG; TSX: DDD; BBSE: DRP) ("the Company") is pleased to announce the
appointment of Ernst & Young LLP ("Ernst & Young") by its Board of Directors as
the Company's independent registered public accounting firm. In addition, the
Board also approved the filing of a listing application with the American Stock
Exchange (AMEX).

The appointment of Ernst & Young is a natural extension of a seven-year
business relationship with Moore Stephens Ellis Foster Ltd. ("Moore Stephens
Ellis Foster") which has been the Company's independent registered public
accounting firm since inception. With the merger of Moore Stephens Ellis Foster
in May 2005, Ernst & Young inherits the thorough understanding of Dragon's
history and business. The Company believes its international growth strategy
will be supported by Ernst & Young's global network and presence.

In addition, the Company's Board also approved the filing of an application to
list its common stock with the American Stock Exchange as soon as practicable.
This will mark an important step for the Company to gain greater visibility and
recognition among the investment community, which will help increase
shareholders' value by providing liquidity and a more credible, stable trading
environment.

The Company believes that the foregoing events will assist in seeking
additional financing from new institutional and strategic investors as
disclosed earlier even though the financing has taken longer than anticipated.
"We are confident in our products and markets. We believe that working with a
top-tier auditing firm and applying for a senior stock exchange listing in the
U.S. will provide a good foundation for the Company to move forward by
enhancing the visibility of the Company, liquidity of our stock and
shareholders' value," said Mr. Yanlin Han, Chairman and CEO of Dragon.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical Inc. is an international pharmaceutical company
headquartered in Vancouver, Canada, with three key business units consisting of
a Pharma division for 44 generic prescription, over-the-counter and sterilized
bulk drugs; a Chemical division for bulk pharmaceutical chemicals and
intermediates (Clavulanic Acid and 7-ACA, Abamectin); and a Biotech division
for recombinant drugs (EPO and G-CSF). The Company has four manufacturing
facilities in China (three in Datong city and one in Nanjing city),
approximately 1,800 employees, plus over 1,200 sales representatives in China,
and approximately 55 key products in 86 different dosages and presentations
currently in the market.

  For further information please contact:

  Dragon Pharmaceutical Inc.
  Garry Wong, CFA, IMBA
  Telephone: [phone] or North America Toll Free: 1-877-388-3784
  Email: 
  Website: http://www.dragonpharma.com/

  or

  Renmark Financial Communications Inc.
  John Boidman : 
  Sylvain Laberge : 
  Media - Cynthia Lane : 
  Telephone: [phone]
  Website: http://www.renmarkfinancial.com/



This press release contains forward looking statements. These statements are
subject to certain risks and uncertainties that could cause actual results to
differ materially from those anticipated in the forward looking statements. No
assurance can be given that the Company's application to list its common stock
with the American Stock exchange will be approved or that the Company will be
able to obtain additional investors. Readers should not place undue reliance on
forward looking statements, which only reflect the view of management as of the
date hereof. The Company does not undertake the obligation to publicly revise
these forward looking statements to reflect subsequent events or circumstances.
Readers should carefully review the risk factors and other factors described in
its periodic reports with the Securities and Exchange Commission. 

DATASOURCE: Dragon Pharmaceutical Inc.



CONTACT: Dragon Pharmaceutical Inc., Garry Wong, CFA, IMBA,

Telephone: [phone] or North America Toll Free: 1-877-388-3784,

Email: , Website: http://www.dragonpharma.com/; or Renmark

Financial Communications Inc., John Boidman: ;

Sylvain Laberge : ;

Media - Cynthia Lane : ,

Telephone: [phone], Website: http://www.renmarkfinancial.com/

Copyright